Home

CARB-X, led by Boston University, is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines.

130+

$million

Invested

45

innovative

Projects

7

different

Countries

12

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

SciBac is fighting fire with fire by using improved bugs as drugs

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

09.03.19

Boston, MA

Annual ASM/ESCMID Conference on Antibiotic Development to Meet the Challenge of AMR

09.04.19

Cambridge, MA

Harvard Museum of Natural History Reception and Mixer

09.06.19

Bilbao, Spain

5th ESCMID Conference on Vaccines

CARB-X News

  • 08.20.2019  |  CARB-X funds Vaxxilon AG to develop a new vaccine to prevent carbapenem-resistant superbug Klebsiella pneumoniae infections full release

  • 08.15.2019  |  CARB-X funds Integrated Biotherapeutics to expand the development of its Staphylococcus aureus vaccine to facilitate use in the developing world full release

  • 07.31.2019  |  CARB-X funds BB100 to develop a unique monoclonal antibody to prevent and treat hyper-virulent multi-drug-resistant E. coli infections full release

See All News

In The News

  • 08.15.2019  |  Vaccine against superbugs could be a game changer, say researchers full story

  • 07.28.2019  |  Insider Q&A – Fighting Antibiotic Resistance, interview with Kevin Outterson, CARB-X Executive Director full story

  • 07.09.2019  |  We can’t despair about our antibiotic crisis full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.